- News & Analysis
- Home
- Latest News
- Reports
- Podcast
- The CVC Funding Round Database
- The CVC Directory
- University
- Video
- Subscribe
- Newsletters
- Events
Page 307
ApoGen applies itself to $7m series A
Washington Research Foundation and Arch Venture Partners are among the investors in the genomic cancer treatment spinout of University of Minnesota.
Dec 14, 2016ApoGen applies itself to $7m series A
AbbVie, Eli Lilly, WuXi PharmaTech, Johnson & Johnson and Alexandria Real Estate Equities are among the investors in the genomic cancer treatment developer.
Dec 14, 2016Mojio revs up series A to $15m
Amazon provided a $7m extension to the connected car technology developer's series A round, which already contained Deutsche Telekom.
Dec 13, 2016BlueRock Therapeutics generates $225m series A
Bayer Lifescience Center joined Versant Ventures to launch BlueRock, a Kyoto spinout that will develop stem cell treatments for cardiovascular diseases and neurodegenerative disorders.
Dec 13, 2016BlueRock Therapeutics generates $225m series A
Bayer Lifescience Center joined Versant Ventures to launch BlueRock, which will develop stem cell treatments for cardiovascular diseases and neurodegenerative disorders.
Dec 13, 2016Vesper sounds out corporates for $15m series A
Michigan spinout Vesper's investors include Amazon's Alexa Fund, AAC Technologies, Mirae Nano Tech and XinGang Electronics.
Dec 12, 2016Vesper sounds out corporates for $15m series A
Advanced microphone technology developer Vesper's investors include Amazon's Alexa Fund, AAC Technologies, Mirae Nano Tech and XinGang Electronics.
Dec 12, 2016Eutilex utilises Kooksoondang in series A round
Kooksoondang Brewery's GN Tech Venture was among the investors in an $18.9m round that took the anti-tumour therapy developer's total funding to $27.7m.
Dec 12, 2016About us
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
Navigation
test regLogin
Not yet subscribed?
We use cookies to enhance your browsing experience and analyse our traffic. By clicking "Accept All", you consent to our use of cookies. Accept Read MorePrivacy & Cookies PolicyPrivacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.


